1. Home
  2. JBLU vs NTLA Comparison

JBLU vs NTLA Comparison

Compare JBLU & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JetBlue Airways Corporation

JBLU

JetBlue Airways Corporation

HOLD

Current Price

$5.25

Market Cap

1.5B

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$13.82

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JBLU
NTLA
Founded
1998
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Air Freight/Delivery Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.6B
IPO Year
2002
2016

Fundamental Metrics

Financial Performance
Metric
JBLU
NTLA
Price
$5.25
$13.82
Analyst Decision
Sell
Buy
Analyst Count
13
20
Target Price
$4.91
$20.45
AVG Volume (30 Days)
26.9M
3.0M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
27.83
27.43
EPS
N/A
N/A
Revenue
$9,062,000,000.00
$67,671,000.00
Revenue This Year
$12.11
N/A
Revenue Next Year
$6.75
$62.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
16.92
52 Week Low
$3.86
$6.83
52 Week High
$6.46
$28.24

Technical Indicators

Market Signals
Indicator
JBLU
NTLA
Relative Strength Index (RSI) 54.04 48.16
Support Level $4.74 $11.93
Resistance Level $5.66 $14.32
Average True Range (ATR) 0.35 0.97
MACD 0.03 0.08
Stochastic Oscillator 49.03 24.88

Price Performance

Historical Comparison
JBLU
NTLA

About JBLU JetBlue Airways Corporation

JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: